Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,632,824
  • Shares Outstanding, K 1,635,706
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,920 M
  • 60-Month Beta 0.77
  • Price/Sales 3.42
  • Price/Cash Flow 10.75
  • Price/Book 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.03
  • Number of Estimates 5
  • High Estimate 1.07
  • Low Estimate 0.92
  • Prior Year 1.01
  • Growth Rate Est. (year over year) +1.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.54 +5.19%
on 04/25/19
48.80 -4.00%
on 05/03/19
+1.05 (+2.29%)
since 04/17/19
3-Month
44.54 +5.19%
on 04/25/19
54.38 -13.85%
on 03/05/19
-4.82 (-9.33%)
since 02/15/19
52-Week
44.30 +5.76%
on 01/03/19
63.69 -26.44%
on 10/09/18
-5.89 (-11.17%)
since 05/17/18

Most Recent Stories

More News
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL

Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

ABBV : 79.46 (-0.05%)
TEVA : 11.63 (+1.84%)
RHHBY : 32.8400 (+0.71%)
BMY : 46.85 (-0.57%)
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

CELG : 95.42 (-0.09%)
RHHBY : 32.8400 (+0.71%)
BMY : 46.85 (-0.57%)
BIIB : 229.28 (-0.69%)
Watch for Shares of Bristol-Myer Sqb (BMY) to Approach Support at $46.68

Shares of Bristol-Myer Sqb (NYSE:BMY) opened today below their pivot of $47.34 and have already reached the first level of support at $46.90. Analysts will be watching for a cross of the next downside...

BMY : 46.85 (-0.57%)
Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019

--New long-term survival data and health outcomes research on Opdivo in combination with Yervoy in advanced melanoma

BMY : 46.85 (-0.57%)
Keloid Treatment Market Size, Industry Share, Approaches and Forecast By 2024

New York, May 16, 2019: Global is segmented based on the treatments type as, Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Radiation Therapy, Laser Therapy, Interferon Therapy, Intralesional...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 6.4800 (-4.71%)
NVS : 82.70 (+0.30%)
SNOA : 0.81 (-4.12%)
GSK : 39.46 (+0.31%)
BMY : 46.85 (-0.57%)
PRGO : 49.67 (-0.46%)
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

MRK : 78.72 (-0.52%)
EXEL : 19.33 (-2.32%)
PFE : 41.47 (-0.41%)
BMY : 46.85 (-0.57%)
Hilliard & Shadowen, LLP Report Prominent AIDS Activists Join Lawsuit Challenging Anticompetitive Practices By Gilead And Other Companies

Today, AIDS activists Gregg Gonsalves, Brenda Goodrow, Andrew Spieldenner, Peter Staley, Robert Vázquez, and Jason Walker joined with other consumers in filing an antitrust complaint in federal court...

GILD : 66.36 (+0.88%)
BMY : 46.85 (-0.57%)
Hilliard & Shadowen, LLP Report Coalition Of Consumers, Activists, And Payors Sues Gilead And Other Manufacturers For Anticompetitive Practices On HIV Medicines

Today a coalition of consumers, AIDS activists, and union health & welfare funds filed an antitrust complaint in federal court in San Francisco against some of the nation's largest pharmaceutical manufacturers,...

GILD : 66.36 (+0.88%)
BMY : 46.85 (-0.57%)
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers

Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers

BLK : 441.56 (-1.27%)
IPG : 22.53 (+0.27%)
NOC : 306.69 (+0.65%)
PGR : 77.72 (-0.17%)
BMY : 46.85 (-0.57%)
Award-Winning Actor and Producer Sterling K. BrownJoins Bristol-Myers Squibb in Effort to Share Stories of What It's Like to Live with Cancer Today

Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life...

BMY : 46.85 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 47.53
1st Resistance Point 47.19
Last Price 46.85
1st Support Level 46.55
2nd Support Level 46.25

See More

52-Week High 63.69
Fibonacci 61.8% 56.28
Fibonacci 50% 53.99
Fibonacci 38.2% 51.71
Last Price 46.85
52-Week Low 44.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar